Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Latanoprost

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Latanoprost

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,266,963Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution
    Glenmark Pharmaceuticals launches Latanoprost Ophthalmic Solution

    14 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/glenmark-pharmaceuticals-inc-usa-launches-latanoprost-ophthalmic-solution-0-005-0-05-mgml-302377022.html

    PR NEWSWIRE
    14 Feb 2025
    Share Share
    Gland Pharma secures FDA approval for Latanoprost Solution
    Gland Pharma secures FDA approval for Latanoprost Solution

    03 Dec 2024

    // EXPRESSPHARMA

    https://www.expresspharma.in/gland-pharma-secures-us-fda-approval-for-latanoprost-ophthalmic-solution/

    EXPRESSPHARMA
    03 Dec 2024
    Share Share
    Enforcement Report - Week of May 29, 2024
    Enforcement Report - Week of May 29, 2024

    29 May 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-29-2024-87457.pdf

    FDA
    29 May 2024
    Share Share
    Thea Pharma Inc. Launches IYUZEH 0.005% in the U.S.
    Thea Pharma Inc. Launches IYUZEH 0.005% in the U.S.

    26 Sep 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/thea-pharma-inc-launches-iyuzeh-latanoprost-ophthalmic-solution-0-005-in-the-us-301938385.html

    PR NEWSWIRE
    26 Sep 2023
    Share Share
    Cayman Chemical Receives CEP for Latanoprost API from EDQM
    Cayman Chemical Receives CEP for Latanoprost API from EDQM

    12 Sep 2023

    // PRESS RELEASE

    https://www.caymanchem.com/news/cayman-chemical-receives-cep-for-latanoprost-api-from-edqm

    PRESS RELEASE
    12 Sep 2023
    Share Share
    IYUZEH Demonstrated Similar IOP Lowering Efficacy when Compared to Xalatan
    IYUZEH Demonstrated Similar IOP Lowering Efficacy when Compared to Xalatan

    03 Mar 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/iyuzeh-latanoprost-ophthalmic-solution-0-005-the-first-and-only-preservative-free-latanoprost-ophthalmic-solution-demonstrated-similar-iop-lowering-efficacy-with-a-favorable-safety-profile-when-compared-to-xalatan-in-patien-301761686.html

    PR NEWSWIRE
    03 Mar 2023
    Share Share